Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral utidelone capsules in advanced solid tumors
CTR20244187Phase 2Active
- Sponsor
- 成都华昊中天药业有限公司/ 北京华昊中天生物医药股份有限公司
- Start
- Nov 2024
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in gastric cancer (GC), gastroesophageal junction adenocarcinoma, cholangiocarcinoma (CCA), ovarian cancer, Esophageal Squamous Cell Carcinoma (ESCC), sponsored by 成都华昊中天药业有限公司/ 北京华昊中天生物医药股份有限公司. Started Nov 2024; status: active.
02
Drugs
utidelone
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomacholangiocarcinoma (CCA)ovarian cancerEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20244187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244187.